IL181634A - Topical Pharmaceuticals containing 8-pyrazolylmethyl-7,3,1-trihydroporin-6,2-wound healing treatment - Google Patents

Topical Pharmaceuticals containing 8-pyrazolylmethyl-7,3,1-trihydroporin-6,2-wound healing treatment

Info

Publication number
IL181634A
IL181634A IL181634A IL18163407A IL181634A IL 181634 A IL181634 A IL 181634A IL 181634 A IL181634 A IL 181634A IL 18163407 A IL18163407 A IL 18163407A IL 181634 A IL181634 A IL 181634A
Authority
IL
Israel
Prior art keywords
trihydropurine
pyrazolylmethyl
pharmaceutical compositions
wound healing
topical pharmaceutical
Prior art date
Application number
IL181634A
Other languages
English (en)
Hebrew (he)
Other versions
IL181634A0 (en
Original Assignee
Gilead Sciences Inc
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Gilead Palo Alto Inc filed Critical Gilead Sciences Inc
Publication of IL181634A0 publication Critical patent/IL181634A0/en
Publication of IL181634A publication Critical patent/IL181634A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL181634A 2004-09-01 2007-02-28 Topical Pharmaceuticals containing 8-pyrazolylmethyl-7,3,1-trihydroporin-6,2-wound healing treatment IL181634A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
IL181634A0 IL181634A0 (en) 2007-07-04
IL181634A true IL181634A (en) 2015-05-31

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181634A IL181634A (en) 2004-09-01 2007-02-28 Topical Pharmaceuticals containing 8-pyrazolylmethyl-7,3,1-trihydroporin-6,2-wound healing treatment

Country Status (21)

Country Link
US (1) US20060058322A1 (enExample)
EP (1) EP1789053B1 (enExample)
JP (2) JP4929173B2 (enExample)
KR (1) KR101247528B1 (enExample)
CN (1) CN101043889B (enExample)
AU (1) AU2005282860B2 (enExample)
CA (1) CA2578702A1 (enExample)
DK (1) DK1789053T3 (enExample)
ES (1) ES2387653T3 (enExample)
HR (1) HRP20120712T1 (enExample)
IL (1) IL181634A (enExample)
MX (1) MX2007002437A (enExample)
NO (1) NO20071718L (enExample)
NZ (1) NZ553487A (enExample)
PL (1) PL1789053T3 (enExample)
PT (1) PT1789053E (enExample)
RS (1) RS52455B (enExample)
RU (1) RU2385322C2 (enExample)
SI (1) SI1789053T1 (enExample)
WO (1) WO2006028810A2 (enExample)
ZA (1) ZA200701777B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
CN101039677A (zh) 2004-10-15 2007-09-19 Cv医药有限公司 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7625881B2 (en) * 2005-06-16 2009-12-01 Gilead Palo Alto, Inc. Prodrugs of A2B adenosine receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
CA2718983C (en) * 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
IL277144B2 (en) * 2018-03-05 2024-06-01 Teon Therapeutics Inc Adenosine receptor antagonists and uses thereof
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
JP2023540740A (ja) * 2020-09-04 2023-09-26 テオン セラピューティクス，インク． アデノシンａ２ｂ受容体アンタゴニストの共結晶

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
AU2001238342A1 (en) * 2000-02-17 2001-08-27 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
KR100937620B1 (ko) * 2001-11-09 2010-01-20 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists

Also Published As

Publication number Publication date
ES2387653T3 (es) 2012-09-27
WO2006028810A2 (en) 2006-03-16
JP2008511654A (ja) 2008-04-17
MX2007002437A (es) 2007-08-14
JP2011246492A (ja) 2011-12-08
CN101043889A (zh) 2007-09-26
RU2385322C2 (ru) 2010-03-27
IL181634A0 (en) 2007-07-04
RS52455B (sr) 2013-02-28
PL1789053T3 (pl) 2012-12-31
CN101043889B (zh) 2010-11-03
EP1789053B1 (en) 2012-06-13
EP1789053A2 (en) 2007-05-30
PT1789053E (pt) 2012-08-09
NO20071718L (no) 2007-03-30
HRP20120712T1 (hr) 2012-10-31
HK1107261A1 (en) 2008-04-03
DK1789053T3 (da) 2012-08-06
KR101247528B1 (ko) 2013-04-15
AU2005282860A1 (en) 2006-03-16
SI1789053T1 (sl) 2012-09-28
JP4929173B2 (ja) 2012-05-09
CA2578702A1 (en) 2006-03-16
NZ553487A (en) 2010-09-30
KR20070047816A (ko) 2007-05-07
US20060058322A1 (en) 2006-03-16
AU2005282860B2 (en) 2012-03-22
WO2006028810A3 (en) 2006-09-28
ZA200701777B (en) 2008-09-25
RU2007107605A (ru) 2008-09-10

Similar Documents

Publication Publication Date Title
IL181634A (en) Topical Pharmaceuticals containing 8-pyrazolylmethyl-7,3,1-trihydroporin-6,2-wound healing treatment
IL184045A0 (en) Compositions for wound healing
IL247484A0 (en) Gel preparations for local administration
IL176014A0 (en) Azepinoindole derivatives as pharmaceutical agents
EP1833467A4 (en) PHARMACEUTICAL COMPOSITIONS FOR SLEEP DISORDERS
TWI341202B (en) Endoparasiticidal compositions for topical application
IL173571A0 (en) Injectable, oral, or topical sustained release pharmaceutical formulations
GB0524962D0 (en) Topical pharmaceutical compositions
EP1648364A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION
AP2006003784A0 (en) Novel compositions for topical delivery
GB0817929D0 (en) Compositions for topical treatment
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
IL181022A0 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
EP1625844A4 (en) COMPOSITION FOR EXTERNAL USE BY PERCUTANEOUS ADMINISTRATION
IL177366A0 (en) Substituted azetidine compounds as cyclooxygease-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
AU2003224482A8 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
EP1941880A4 (en) A PYRIDONE CARBOXYLIC ACID DERIVATIVE LOTION
IL170315A (en) Cycloalkyl-substituted alkanoic acid derivatives, pharmaceutical compositions and use thereof
PL1791872T3 (pl) Biotynylowane heksadekasacharydy, kompozycje farmaceutyczne i ich zastosowanie
HU0304095D0 (en) Novel, effective pharmaceutical compositions
GB0219153D0 (en) Substituted glycine derivatives for use as medicaments
SG147453A1 (en) Pharmaceutical aerosol compositions
EP1850829A4 (en) NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS
ZA200706710B (en) 6-Phenylhex-5-enoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed